Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$573000.0.

  • Barinthus Biotherapeutics' Change in Accured Expenses rose 7852.32% to -$573000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 7156.64%. This contributed to the annual value of $456000.0 for FY2024, which is 7711.99% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Change in Accured Expenses is -$573000.0, which was up 7852.32% from -$245000.0 recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Change in Accured Expenses peaked at $5.6 million during Q3 2022, and registered a low of -$4.3 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$108000.0 (2021), whereas its average is $225105.3.
  • Over the last 5 years, Barinthus Biotherapeutics' Change in Accured Expenses had its largest YoY gain of 272037.04% in 2022, and its largest YoY loss of 47963.39% in 2022.
  • Over the past 5 years, Barinthus Biotherapeutics' Change in Accured Expenses (Quarter) stood at $2.6 million in 2021, then tumbled by 267.83% to -$4.3 million in 2022, then rose by 24.89% to -$3.2 million in 2023, then surged by 161.22% to $2.0 million in 2024, then crashed by 128.88% to -$573000.0 in 2025.
  • Its Change in Accured Expenses stands at -$573000.0 for Q3 2025, versus -$245000.0 for Q2 2025 and -$2.5 million for Q1 2025.